CAChul-Soo Ahn

Chul-Soo Ahn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chul-Soo Ahn has a total of 122 co-authors. Here are the top co-authors by number of shared publications:

  • Shin Hwang

    Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    96 shared publications
  • Dong-Hwan Jung

    Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    89 shared publications
  • Gi-Won Song

    Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    88 shared publications
  • Deok-Bog Moon

    Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    84 shared publications
  • Tae-Yong Ha

    Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    82 shared publications
  • Gil-Chun Park

    Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    81 shared publications

Latest Publications

  • Bilateral duct-to-duct anastomosis in dual left graft living donor liver transplantation: Bile duct position assessment after graft procurement and perfusion—A retrospective cohort study

    by Woo-Hyoung Kang, Deok-Bog Moon, Chul-Soo Ahn, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Shin Hwang, Ki-Hun Kim, Young-In Yoon, et al.

    In adult dual left liver graft living donor liver transplantation (LDLT), composite rotation of the right-sided graft alters the bile duct–portal vein relationship, making bilateral duct-to-duct (D-D) reconstruction technically challenging. Although bilateral D-D preserves endoscopic access and avoids enteric reconstruction, no structured intraoperative strategy has been established. From 36 consecutive dual left graft LDLT procedures, we propose a practical approach based on bile duct–portal vein positional patterns and a 2-stage intraoperative assessment. Bilateral D-D was achieved in 26 patients (72.2%) without bile leak. Biliary stricture occurred in 38.5% and was managed endoscopically in 88.9% without surgical reintervention. Portal vein narrowing developed in 8 patients (22.2%), most often when the right graft bile duct lay deeply posterior to the portal vein after rotation (55.6% vs. 11.1%–12.5% in other patterns). Among patients with narrowing and long-term follow-up, all 4 conservatively managed grafts developed right graft atrophy, whereas none of the 3 managed with intraoperative portal vein stenting did; no mortality was attributable to narrowing. Bilateral D-D is therefore achievable when guided by intraoperative assessment of the bile duct–portal vein relationship after composite rotation: hepaticojejunostomy should be performed without hesitation in unfavorable configurations, and intraoperative portal vein stenting should be considered selectively when narrowing is detected. In carefully selected patients, bilateral D-D is a feasible strategy that preserves endoscopic access; these single-center observations are exploratory and warrant prospective validation.

  • Open Access

    Outcomes of liver transplantation in critically ill patients admitted to an intensive care unit: a retrospective study

    by Dae-Hyeon Won, Young-In Yoon, Sung-Min Kim, Shin Hwang, Chul-Soo Ahn, Ki-Hun Kim, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, et al.

    Dae-Hyeon Won, Young-In Yoon, Sung-Min Kim, Shin Hwang, Chul-Soo Ahn, Ki-Hun Kim, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Sung-Gyu Lee. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.26.0010

  • Open Access

    AFP-PIVKA-II score as a simplified quantifiable surrogate biomarker for hepatocellular carcinoma recurrence following living donor liver transplantation

    by Dae Hyeon Won, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Young-In Yoon, et al.

    Dae Hyeon Won, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Young-In Yoon, Sung-Gyu Lee. Ann Liver Transplant -0001;0:. https://doi.org/10.52604/alt.25.0024

  • Open Access

    Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma

    by I-Ji Jeong, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Young-In Yoon, et al.

    BACKGROUND Intrahepatic cholangiocarcinoma (ICC) can be an incidental finding in liver explants following liver transplantation (LT). This study aimed to evaluate the long-term post-transplant outcomes of patients with ICC. MATERIAL AND METHODS From 2003 to 2022, 25 patients with ICC were identified among 6,611 adult LT recipients through institutional database search. RESULTS The incidence of ICC among adult LT recipients was 0.4%. All cases were incidental findings in explanted livers. The mean ICC tumor size was 2.7±1.6 cm, and 22 patients had single ICC lesion. Concurrent second liver malignancies were found in 10 patients (40%): hepatocellular carcinoma (HCC) in 9 and combined HCC-cholangiocarcinoma in one. The 5-year all-type tumor recurrence (TR) and overall survival (OS) rates were 72.0% and 47.0%, respectively. The presence of second primary cancer had no significant impact on TR (P=0.832) or OS (P=0.533). Similarly, ICC tumor stage did not significantly affect TR (P=0.394) or OS (P=0.395). Among 15 patients with ICC alone, 11 (73.3%) experienced ICC recurrence. Of the 10 patients with concurrent malignancies, 7 (70.0%) experienced all-type TR: 5 with HCC and 2 with ICC. Notably, the 5-year ICC recurrence and OS rates in 5 patients with very early-stage ICC and no HCC recurrence were 20.0% and 80.0%, respectively. CONCLUSIONS ICC is a rare incidental finding in LT recipients, often coexisting with concurrent second liver malignancy. Overall prognosis following LT for ICC remains poor, except for those with very early-stage disease. Because all incidences of TR occurred within 5 years after transplant, rigorous surveillance is essential during this period.

  • Open Access

    Long-Term Patency of Hemashield Vascular Grafts Used for Middle Hepatic Vein Reconstruction During Living-Donor Liver Transplantation: A Single-Center Korean Experience

    by Dae Hyeon Won, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Young-In Yoon, et al.

    BACKGROUND The availability of homologous vein allografts is limited. Therefore, prosthetic vascular grafts can be used as alternatives for middle hepatic vein (MHV) reconstruction during living-donor liver transplantation (LDLT). This study evaluated the short- and long-term patency of MHV reconstructions using Hemashield vascular grafts and assessed their effect on post-transplant survival. MATERIAL AND METHODS This retrospective observational study included 149 adult LDLT recipients who underwent MHV reconstruction using Hemashield grafts at a single institution. Graft patency and survival outcomes were assessed over long-term follow-up. RESULTS The mean recipient age was 56.2±7.7 years, and the mean graft-to-recipient weight ratio was 1.06±0.25. V5 reconstruction was achieved through single, double, and triple anastomoses in 111, 32, and 2 patients, respectively. V8 reconstruction in 116, 20, and one patient was achieved through single, double, and triple anastomoses, respectively. In 100 and 49 cases, we used Hemashield grafts with diameters of 10 mm and 12 mm, respectively. Three patients (2.0%) developed early thrombosis that necessitated stent placement. The cumulative conduit occlusion-free survival rates were 81.0% at 3 months, 57.9% at 1 year, 48.7% at 3 years, and 43.8% at 5 years. Overall patient survival rates were 95.3% at 1 year, 89.1% at 3 years, and 85.7% at 5 years. No cases of graft migration or conduit-related infection were identified. CONCLUSIONS MHV reconstruction using Hemashield grafts demonstrated acceptable short- and long-term patency, with no migration or infection. These findings support the use of Hemashield grafts as a reliable and effective prosthetic option for MHV reconstruction during LDLT.

  • Open Access

    ADV score plus FDG-PET as preoperative predictors of post-resection prognosis in patients with hepatocellular carcinoma ≥10 cm: a retrospective cohort validation study

    by I-Ji Jeong, Shin Hwang, Byung-Gon Nah, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Ki-Hun Kim, et al.

    Background: The ADV score, calculated by multiplying α-fetoprotein, des-γ-carboxy prothrombin, and tumor volume (TV), is a surrogate marker for post-resection prognosis in hepatocellular carcinoma (HCC). 2- 18 F-fluoro-2-deoxy- d -glucose (FDG) positron emission tomography (PET) reflects the tumor biology. This study aimed to validate prognostic prediction models (PPMs) that combined the ADV score and FDG-PET in patients undergoing resection for large HCC tumors (≥10 cm). Methods: Of the 7905 patients who underwent resection for HCC between 2009 and 2018, 412 with solitary tumors ≥10 cm were analyzed. Results: The median pathological and radiological tumor diameters and TVs were 12.0 and 11.0 cm and 575 and 696 mL, respectively. The median values of pathological, radiological and volumetric TVs converged at 2.8log mL; therefore, radiological TV was selected. At 1, 3, 5, and 10 years, the tumor recurrence (TR) rates were 60.7, 72.2, 76.6, and 85.1%, respectively, and the overall survival (OS) rates were 77.7, 56.5, 48.2, and 35.5%, respectively. Independent risk factors for TR included viral hepatitis, hypermetabolic PET, microvascular invasion (MVI), and satellite nodules. Hypermetabolic PET, MVI, satellite nodules, and cirrhosis were significant predictive factors of OS. The ADV scores, expressed in 2.0log-intervals, showed a clear prognostic separation of TR and OS. Combining the ADV score with FDG-PET activity further improved the predictive accuracy, leading to two PPMs: a two-tiered model (hypermetabolic PET with ADV ≥7.0log vs. others) and a four-tiered model (isometabolic PET and hypermetabolic PET stratified by ADV <7.0log, ≥7.0log and <11.0log, and ≥11.0log). Conclusions: These two PPMs reliably predicted post-resection outcomes in patients with large HCC, making them useful tools for guiding surgical decisions and postoperative surveillance in high-risk patients.


  • Open Access

    Prognostic validation of ADV and MoRAL scores for hepatocellular carcinoma recurrence following living donor liver transplantation: a long-term follow-up study

    by Young-In Yoon, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Sung-Gyu Lee

    Young-In Yoon, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Sung-Gyu Lee. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.25.0063


  • Open Access

    Long-Term Prognostic Significance of TACE-Induced Complete Pathological Response in Patients with Hepatocellular Carcinoma Who Have Undergone Liver Transplantation

    by I-Ji Jeong, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Young-In Yoon, et al.

    BACKGROUND Complete pathological response (CPR) after transcatheter arterial chemoembolization (TACE) is associated with improved posttransplant outcomes in patients with hepatocellular carcinoma (HCC). This study evaluated the prognostic significance of TACE-induced CPR in patients with HCC who underwent liver transplantation (LT). MATERIAL AND METHODS The records of 2238 patients who underwent primary LT for HCC between January 2006 and December 2020 were retrospectively reviewed; of these, 253 achieved explant pathology-confirmed TACE-induced CPR. Their clinical outcomes were analyzed. RESULTS These 253 patients underwent an average of 2.2±2.3 TACE sessions. The median number of non-viable tumors was 1, and the median maximal tumor size was 1.6 cm. At 1, 3, 5, 10, and 15 years, cumulative post-LT recurrence rates were 1.2%, 3.3%, 3.3%, 5.6%, and 5.6%, respectively; overall patient survival rates were 96.0%, 93.7%, 92.4%, 91.3%, and 82.1%, respectively. Larger tumors (>2 cm) and multiple non-viable tumors were independently associated with higher recurrence and reduced survival rates (P≤0.036). Cluster analysis identified patients with multiple non-viable tumors larger than 2 cm as a high-risk group; others comprised a low-risk group. Recurrence (P<0.001) and survival (P=0.018) rates were significantly lower in the high-risk group than in the low-risk group. CONCLUSIONS TACE-induced CPR is a strong prognostic indicator of favorable long-term outcomes after LT in patients with HCC. Stratification based on non-viable tumor size and number can identify high-risk patients with CPR who require closer surveillance. Less intensive follow-up may be sufficient for low-risk patients.

  • Open Access

    Donor-to-recipient sex match status has no prognostic effect on long-term survival following liver transplantation: a retrospective observational study

    by Woo-Hyoung Kang, I-Ji Jeong, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Young-In Yoon, et al.

    Woo-Hyoung Kang, I-Ji Jeong, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Young-In Yoon, Sung-Gyu Lee. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.25.0049

  • Open Access

    Long-Term Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma After Liver Transplantation in Patients with or without Concurrent Hepatocellular Carcinoma

    by I-Ji Jeong, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Young-In Yoon, et al.

    BACKGROUND Combined hepatocellular carcinoma-cholangiocarcinoma (CHC), a rare disease, is usually an incidental diagnosis after liver transplantation (LT). In this study, we investigated the long-term post-transplant outcomes of CHC patients. MATERIAL AND METHODS From 2000 to 2022, 60 CHC patients were identified from a single-center database containing 6985 adult LT cases. RESULTS The incidence of CHC in adult LT patients was 0.9%. All CHC cases, except 1, were diagnosed incidentally in explanted livers. The mean CHC tumor diameter was 2.5±1.7 cm, and 51 recipients (85.0%) had a single tumor. Viable hepatocellular carcinoma (HCC) co-existed CHC in 23 patients (38.3%). The 5-year all-type tumor recurrence (TR) and overall survival (OS) rates were 37.9% and 57.7%, respectively. The presence of concurrent HCC did not affect all-type TR (p=0.228) or OS (p=0.083). The tumor stage of CHC was a significant prognostic factor for TR (p=0.017) and OS (p=0.038). In 37 patients with CHC alone, TR occurred in 13 (35.1%). In 23 patients with concurrent HCC, all-type TR occurred in 11 cases (47.8%). The 5-year TR and OS rates for 17 patients with very early-stage CHC without concurrent HCC were 17.6% and 82.4%, respectively. CONCLUSIONS CHC is a rare diagnosis following LT, and 38.3% of patients in this study had concurrent HCC. The post-transplant prognosis of CHC was unfavorable, except for patients with very early-stage CHC. Given that the majority of recurrences occur within the first 5 years after transplantation, intensive surveillance is crucial during this high-risk period. Patients with very early-stage CHC may be appropriate candidates for LT.